Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APG-1387 + gemcitabine + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Ascentage Pharma
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
APG-1387 + gemcitabine + nab-paclitaxel is an investigational combination regimen for advanced pancreatic cancer, combining three agents: APG-1387 (a novel small molecule SMAC mimetic and antagonist of inhibitor of apoptosis proteins, IAPs), gemcitabine (a nucleoside analog antimetabolite chemotherapeutic), and nab-paclitaxel (albumin-bound paclitaxel, a microtubule stabilizer). APG-1387, developed by Ascentage Pharma, promotes apoptosis in tumor cells by degrading cIAP1/2 and XIAP to sensitize tumors to cytotoxic agents. Gemcitabine inhibits DNA synthesis to induce cytotoxicity, while nab-paclitaxel disrupts microtubule function to arrest cell division. The combination aims to enhance anticancer efficacy and overcome chemo-resistance by simultaneously activating pro-apoptotic pathways and blocking tumor proliferation. This combination is currently being studied in phase Ib/II trials for advanced pancreatic cancer[3][5].
- Other names
- nanodispersed paclitaxelnanoparticle albumin-bound paclitaxel2′,2′-difluorodeoxycytidine
02
Targets
BIRC7DNA polymerase familyBIRC2 (Cellular inhibitor of apoptosis protein 1)BIRC3 (Baculoviral IAP repeat-containing protein 3)TUBB (Tubulin (alpha and beta subunits))XIAP (Baculoviral IAP repeat-containing protein 4)
Beyond the preview
Go deeper on APG-1387 + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APG-1387 + gemcitabine + nab-paclitaxel.